Eukaryotic cell, method for producing eukaryotic cell, and pharmaceutical composition
By using eukaryotic cells engineered with synthesized nucleic acids to produce infectious viruses in vivo, the challenges of endogenous antibody interference and costly quality control are addressed, facilitating efficient and cost-effective therapeutic virus production for treatments like gene therapy and oncolytic virus therapy.
Patent Information
- Application Number
- PCT/JP2024/017873
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-14
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current methods for producing infectious viruses for therapeutic use, such as gene therapy and oncolytic virus therapy, are hindered by the weakening effect of endogenous neutralizing antibodies and require costly and time-consuming quality control processes, including ultrafiltration and ultracentrifugation, which delay drug development and increase prices.
Eukaryotic cells are engineered in vivo with artificially synthesized nucleic acids encoding virus genomes, allowing for the production of infectious viruses within the body, thereby avoiding neutralizing antibodies and simplifying the manufacturing process by using mesenchymal stem cells with tissue tropism for targeted delivery and reducing the need for extensive virus concentration and purification.
This approach enables efficient, cost-effective production of infectious viruses with reduced invasiveness to normal cells and enhanced therapeutic efficacy by producing viral particles directly in vivo, minimizing delays and costs associated with conventional virus production methods.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
Eukaryotic cells, methods for producing eukaryotic cells, and pharmaceutical compositions
[0001] The present invention relates to eukaryotic cells capable of producing infectious viruses in vivo using artificial synthetic nucleic acids, a method for producing eukaryotic cells, and pharmaceutical compositions.
[0002] Examples of the application of infectious viruses as therapeutic agents include gene therapy and oncolytic virus therapy. The former is a viral vector in which a foreign gene for disease treatment is inserted into the viral genome, while the latter is a cancer therapeutic agent that utilizes the cancer cell-destroying ability of certain viruses called oncolytic viruses. To date, the usefulness of retroviruses, lentiviruses, adeno-associated viruses, adenoviruses, herpes simplex viruses, coxsackie viruses, measles viruses, and the like as therapeutic agents has been reported. Furthermore, for clinical use, it is desirable to control viral proliferation in vivo by genetically modifying the virus to limit viral proliferation in normal cells and reduce side effects. For example, genetic modification is often performed to implement safety measures, such as creating viruses with tropism for efficient proliferation in specific tissues or cells, or non-transmissible viruses that do not infect nearby cells (Non-Patent Document 1).
[0003] https: / / www.nature.com / articles / s41392-023-01408-5https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC2787715 /
[0004] In general, infectious viruses for disease treatment can be produced by preparing artificially synthesized nucleic acids, such as DNA or RNA, encoding the viral genome and then transfecting them into virus-producing cells by chemical or non-chemical methods. The resulting infectious viruses are typically administered topically or intravenously. However, because some of these infectious viruses cause opportunistic infections, clinical application poses the problem of diminished therapeutic efficacy due to the influence of endogenous neutralizing antibodies. To address this issue, a method has been developed in which the infectious virus is infected ex vivo into mesenchymal stem cells or the like, and the infected mesenchymal stem cells or the like are then administered to circumvent endogenous neutralizing antibodies against the virus (Non-Patent Document 2). However, the present inventors recognized that clinical application requires steps such as concentrating the resulting infectious virus by ultrafiltration or purifying it by ultracentrifugation or chromatography. This method requires time and cost to produce the virus and establish the associated quality control system, potentially leading to delays in development or rising prices for therapeutic drugs.
[0005] An object of the present invention is to provide eukaryotic cells capable of producing viruses in vivo, a method for producing eukaryotic cells, and pharmaceutical compositions.
[0006] The eukaryotic cell of the present invention is a eukaryotic cell provided in a living body, the eukaryotic cell containing an artificial synthetic nucleic acid encoding the entire genome or a part thereof of an infectious virus, and the artificial synthetic nucleic acid being capable of producing an infectious virus in the living body.
[0007] In the present invention, the eukaryotic cells may be those in which no infectious virus is expressed due to the artificial synthetic nucleic acid.
[0008] In the present invention, the artificial synthetic nucleic acid may be composed of artificially synthesized DNA or RNA.
[0009] In the present invention, the artificial synthetic nucleic acid may contain a foreign gene intended for the treatment or prevention of a disease, including cancer or a precancerous condition.
[0010] In the present invention, the infectious virus may be at least one selected from the group consisting of Retroviridae, Adenoviridae, Picornaviridae, Herpesviridae, Coronaviridae, Paramyxoviridae, Parvoviridae, Reoviridae, Poxviridae, Retroviridae, and Rhabdoviridae.
[0011] In the present invention, the eukaryotic cells may be used in the treatment or prevention of diseases including cancer or precancerous conditions.
[0012] In the present invention, the eukaryotic cells can be derived from any of mammalian tissues including blood, skin, epithelium, umbilical cord, placenta, bone marrow, fat, dental pulp, and amniotic membrane.
[0013] In the present invention, the eukaryotic cells can be derived from either blood cells or stem cells.
[0014] The method for producing eukaryotic cells of the present invention is a method for producing eukaryotic cells to be provided in a living body, and comprises a step of genetically introducing an artificial synthetic nucleic acid encoding the entire genome or a part thereof of an infectious virus into the eukaryotic cells by chemical or non-chemical means, wherein the artificial synthetic nucleic acid is capable of producing an infectious virus in the living body. The pharmaceutical composition of the present invention comprises the eukaryotic cells of the present invention.
[0015] The pharmaceutical compositions of the present invention can be formulated for local or systemic administration.
[0016] According to the present invention, in order to produce infectious viruses applicable to gene therapy or cancer therapeutic drugs, eukaryotic cells containing the prepared artificial synthetic nucleic acid are administered, and viral particles that evade endogenous neutralizing antibodies and have infectious and therapeutic effects can be produced in vivo.
[0017] Preferred embodiments of the present invention will now be described in detail.
[0018] The eukaryotic cells according to the embodiments are intended to be used in vivo. The eukaryotic cells contain artificial synthetic nucleic acids that encode the entire genome or a portion thereof of an infectious virus. The artificial synthetic nucleic acids are capable of producing infectious viruses in vivo. Methods for synthesizing artificial synthetic nucleic acids can be realized by known methods. Methods for introducing artificial synthetic nucleic acids into eukaryotic cells include gene transfer using known chemical or non-chemical methods. The eukaryotic cells according to the embodiments are ones in which infectious viruses are not expressed due to the artificial synthetic nucleic acids.
[0019] Artificial synthetic nucleic acids can be composed of artificially synthesized DNA or RNA. Artificial synthetic nucleic acids can contain foreign genes intended for the treatment or prevention of diseases, including cancer or precancerous conditions. Eukaryotic cells are used for the treatment or prevention of diseases, including cancer or precancerous conditions.
[0020] The infectious virus can be at least one selected from the group consisting of Retroviridae, Adenoviridae, Picornaviridae, Herpesviridae, Coronaviridae, Paramyxoviridae, Parvoviridae, Reoviridae, Poxviridae, Retroviridae, and Rhabdoviridae.
[0021] The eukaryotic cells can be derived from any of mammalian tissues: blood, skin, epithelium, umbilical cord, placenta, bone marrow, fat, dental pulp, and amniotic membrane. The eukaryotic cells can be derived from blood cells or stem cells. Examples of blood cells include T cells, B cells, monocytes, dendritic cells, neutrophils, platelets, and erythroblasts. Examples of stem cells include hematopoietic stem cells, mesenchymal stem cells, muse cells, embryonic stem cells, and induced pluripotent stem cells. Mesenchymal stem cells are particularly preferred as eukaryotic cells.
[0022] The method for producing eukaryotic cells according to the embodiment is a method for producing eukaryotic cells to be used in vivo, particularly for the treatment of disease. The method for producing eukaryotic cells may include a step of genetically introducing an artificial synthetic nucleic acid encoding the entire genome or a part of an infectious virus into a eukaryotic cell by chemical or non-chemical means. The artificial synthetic nucleic acid is capable of producing an infectious virus in vivo.
[0023] A pharmaceutical composition according to an embodiment of the present invention comprises a eukaryotic cell according to an embodiment of the present invention, which produces an infectious virus in vivo. The pharmaceutical composition can be prepared as a formulation for local or systemic administration. An infectious virus encoded by an artificial synthetic nucleic acid is produced in vivo, thereby realizing a pharmaceutical composition applicable to the treatment of disease. Specifically, the artificial synthetic nucleic acid is transfected into a eukaryotic cell by chemical or non-chemical means and then injected into the body locally or systemically. The eukaryotic cell containing the artificial synthetic nucleic acid is then delivered to a target cell, where the virus produced in the eukaryotic cell is released and exerts its medicinal effect.
[0024] The eukaryotic cells according to the embodiment are preferably mammalian cells or fish cells.
[0025] According to this embodiment, infectious viruses can be produced by administering eukaryotic cells containing artificial synthetic nucleic acids consisting of DNA or RNA into a living body. The use of such artificial synthetic nucleic acids significantly reduces the manufacturing and quality control procedures required for conventional virus production, and if the entire viral genome or a portion of it is known, treatment can be provided in a very short period of time and at low cost. Furthermore, according to this embodiment, administering eukaryotic cells as carrier cells can prevent the development of endogenous neutralizing antibodies against the virus.
[0026] In particular, when the eukaryotic cells are mesenchymal stem cells, the artificial synthetic nucleic acid can be efficiently delivered to the local cancer site due to its tissue-specificity, and the induction of RNA interference can have the effect of being less invasive to normal cells.
[0027] This embodiment can be modified in various ways within the scope of the present invention.
Claims
1. A eukaryotic cell to be provided in a living organism, said eukaryotic cell comprising an artificial synthetic nucleic acid encoding the entire genome or a part thereof of an infectious virus, said artificial synthetic nucleic acid being capable of producing the infectious virus in said living organism.
2. As claimed in claim 1, wherein the eukaryotic cell is a eukaryotic cell in which no infectious virus is expressed by the artificial synthetic nucleic acid.
3. A eukaryotic cell according to claim 1, wherein the artificial synthetic nucleic acid is composed of artificially synthesized DNA or RNA.
4. In claim 1, the artificial synthetic nucleic acid is a eukaryotic cell containing an exogenous gene intended for the treatment or prevention of a disease, including cancer or a precancerous condition.
5. A eukaryotic cell according to claim 1, wherein the infectious virus is at least one selected from the group consisting of Retroviridae, Adenoviridae, Picornaviridae, Herpesviridae, Coronaviridae, Paramyxoviridae, Parvoviridae, Reoviridae, Poxviridae, Retroviridae and Rhabdoviridae.
6. The eukaryotic cell according to claim 1, wherein the eukaryotic cell is used for the treatment or prevention of a disease, including cancer or a precancerous condition.
7. The eukaryotic cell according to claim 1, wherein the eukaryotic cell is derived from any one of mammalian tissues including blood, skin, epithelium, umbilical cord, placenta, bone marrow, fat, dental pulp, and amniotic membrane.
8. The method according to claim 1, wherein the eukaryotic cell is derived from either a blood cell or a stem cell.
9. A method for producing eukaryotic cells to be provided in a living body, comprising a step of introducing an artificial synthetic nucleic acid encoding the entire genome or a part thereof of an infectious virus into said eukaryotic cells by chemical or non-chemical means, said artificial synthetic nucleic acid being capable of producing an infectious virus in the living body.
10. A pharmaceutical composition comprising the eukaryotic cell of claim 1.
11. The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is a formulation for local or systemic administration.
Citation Information
Patent Citations
Enhanced systems for cell-mediated oncolytic virus therapy
JP2022520298A
